Oriola Corporation Stock Exchange Release 11 April 2019 at 3:30 p.m.
Oriola’s pro forma figures 2017 - 2018 based on new operating model
On 18 September 2018, Oriola announced that Oriola’s Board of Directors has
approved the company’s new operating model. Oriola’s business has been divided
into three business areas operating in Finland and Sweden: Consumer, Pharma and
Retail. These three business areas are also the Group’s new financial reporting
segments according to IFRS 8. The changes in organisation took effect as of 1
January 2019.
The new business area structure is based on customer focus. Consumer offers
products and services for health and wellbeing for consumers through Kronans
Apotek, the third largest pharmacy chain in Sweden. Pharma provides tailored
logistics, expert and advisory services to pharmaceutical companies, as well as
a wide range of pharmaceutical products to pharmacies, hospital pharmacies and
veterinarians. Retail provides a wide range of health and wellbeing products to
pharmacies, veterinarians, private and public healthcare operators and retailers
as well as dose dispensing, special licence medicines and pharmacy staffing
services.
Oriola’s financial reporting will be aligned with the new operating model
starting from January-March 2019 Interim report, to be published on 26 April
2019. The restated figures for the comparative periods are presented in the
tables below.
Reporting segments, pro forma
Invoicing 2018 2018 2018 2018 2017
EUR million 1-12 1-9 1-6 1-3 1-12
Consumer 769.5 573.7 391.0 193.9 780.5
Pharma 2,697.1 1,972.7 1,322.3 639.0 2,502.2
Retail 431.2 323.8 224.2 113.5 403.5
Invoicing between segments -379.4 -280.9 -192.5 -98.0 -349.8
Total 3,518.4 2,589.2 1,745.0 848.3 3,336.3
Net sales 2018 2018 2018 2018 2017
EUR million 1-12 1-9 1-6 1-3 1-12
Consumer 751.9 561.1 382.3 189.5 762.0
Pharma 749.9 554.5 374.1 183.5 713.2
Retail 429.8 322.8 223.5 113.2 402.3
Net sales between segments -379.4 -280.9 -192.5 -98.0 -349.8
Total 1,552.2 1,157.5 787.5 388.1 1,527.7
EBIT 2018 2018 2018 2018 2017
EUR million 1-12 1-9 1-6 1-3 1-12
Consumer 17.7 14.6 9.8 3.8 25.2
Pharma 21.1 17.0 6.6 3.1 14.0
Retail 1.3 5.9 2.6 1.9 5.7
Group administration and others -18.1 -7.6 -5.5 -3.2 -7.1
Total 22.0 30.0 13.5 5.6 37.8
Adjusted EBIT 2018 2018 2018 2018 2017
EUR million 1-12 1-9 1-6 1-3 1-12
Consumer 18.8 15.8 9.9 4.0 25.2
Pharma 21.1 17.0 6.6 3.1 15.1
Retail 5.9 5.9 2.6 1.9 5.7
Group administration and others -8.9 -7.0 -5.0 -2.7 -6.1
Total 36.9 31.7 14.2 6.2 39.9
Number of personnel 2018 2018 2018 2018 2017
at the end of the period 1-12 1-9 1-6 1-3 1-12
Consumer 1,601 1,598 1,612 1,591 1,581
Pharma 507 506 497 493 502
Retail 530 517 584 544 491
Group administration and others 68 67 65 59 46
Total 2,706 2,688 2,758 2,687 2,619
2018 2018 2018 2018 2017
Average number of personnel 1-12 1-9 1-6 1-3 1-12
Consumer 1,591 1,586 1,571 1,544 1,582
Pharma 506 505 499 504 494
Retail 540 546 548 545 564
Group administration and others 62 60 57 53 47
Total 2,699 2,697 2,675 2,646 2,686
Quarterly 2018 2018 2018 2018 2017 2017 2017 2017
invoicing
EUR million Q4 Q3 Q2 Q1 Q4 Q3 Q2 Q1
Consumer 195.9 182.7 197.1 193.9 193.3 191.6 199.1 196.5
Pharma 724.4 650.4 683.3 639.0 661.4 620.5 631.2 589.1
Retail 107.4 99.6 110.7 113.5 109.0 96.0 102.0 96.5
Invoicing -98.5 -88.5 -94.4 -98.0 -92.2 -84.9 -88.1 -84.6
between
segments
Total 929.1 844.2 896.7 848.3 871.6 823.1 844.2 797.5
Quarterly net 2018 2018 2018 2018 2017 2017 2017 2017
sales
EUR million Q4 Q3 Q2 Q1 Q4 Q3 Q2 Q1
Consumer 190.8 178.8 192.8 189.5 188.7 187.2 194.2 191.9
Pharma 195.4 180.4 190.7 183.5 190.0 179.6 179.7 163.9
Retail 107.1 99.2 110.3 113.2 108.7 95.7 101.7 96.2
Net sales -98.5 -88.5 -94.4 -98.0 -92.1 -84.9 -88.1 -84.6
between
segments
Total 394.7 369.9 399.4 388.1 395.2 377.6 387.5 367.4
Quarterly EBIT 2018 2018 2018 2018 2017 2017 2017 2017
EUR million Q4 Q3 Q2 Q1 Q4 Q3 Q2 Q1
Consumer 3.0 4.9 6.0 3.8 4.2 8.6 7.3 5.1
Pharma 4.1 10.5 3.5 3.1 0.3 1.8 6.0 5.9
Retail -4.6 3.2 0.8 1.9 1.6 1.5 1.2 1.4
Group -10.5 -2.1 -2.3 -3.2 -2.2 -1.2 -1.8 -1.8
administration
and others
Total -8.0 16.5 7.9 5.6 3.9 10.7 12.7 10.5
Quarterly 2018 2018 2018 2018 2017 2017 2017 2017
adjusted EBIT
EUR million Q4 Q3 Q2 Q1 Q4 Q3 Q2 Q1
Consumer 3.0 5.8 6.0 4.0 4.4 7.6 8.0 5.3
Pharma 4.1 10.5 3.5 3.1 1.5 1.8 6.0 5.9
Retail 0.0 3.2 0.8 1.9 1.6 1.5 1.2 1.4
Group -1.9 -2.0 -2.3 -2.7 -1.2 -1.2 -2.1 -1.5
administration
and others
Total 5.2 17.5 7.9 6.2 6.2 9.7 13.0 11.0
Quarterly investments 2018 2018 2018 2018 2017 2017 2017 2017
EUR million Q4 Q3 Q2 Q1 Q4 Q3 Q2 Q1
Consumer 2.7 1.1 2.0 1.1 1.7 2.9 1.6 2.9
Pharma 1.9 1.6 3.0 2.6 3.1 4.9 3.2 2.0
Retail 0.9 0.4 0.3 0.3 2.3 2.6 2.6 5.5
Group administration and others 1.7 3.1 12.1 4.8 2.0 1.8 3.9 3.1
Total 7.2 6.2 17.4 8.8 9.1 12.2 11.3 13.5
Assets 2018 2018 2018 2018 2017
EUR million 31 Dec 30 Sep 30 Jun 31 Mar 31 Dec
Consumer 378.0 396.9 397.5 408.4 424.1
Pharma 324.0 322.3 323.0 325.8 334.2
Retail 117.4 122.7 123.6 121.4 116.3
Group administration and others 108.3 87.3 74.7 71.0 47.8
Total 927.7 929.1 918.8 926.6 922.4
Liabilities 2018 2018 2018 2018 2017
EUR million 31 Dec 30 Sep 30 Jun 31 Mar 31 Dec
Consumer 51.0 49.1 63.2 54.1 58.6
Pharma 508.1 494.7 499.1 488.8 460.8
Retail 51.6 56.3 56.3 69.0 74.3
Group administration and others 135.5 139.2 126.0 142.1 131.0
Total 746.2 739.3 744.6 754.0 724.7
Depreciation, amortisation 2018 2018 2018 2018 2017
and impairments, EUR million 1-12 1-9 1-6 1-3 1-12
Consumer 14.8 11.3 7.8 4.2 17.0
Pharma 4.8 3.4 2.1 1.0 3.9
Retail 4.0 3.0 1.9 1.0 4.5
Group administration and others 0.5 0.3 0.2 0.1 0.3
Total 24.1 18.1 12.0 6.3 25.7
Oriola Corporation
Helena Kukkonen
CFO
Further information:
Helena Kukkonen
CFO
Tel. +358 10 429 2112
Email: helena.kukkonen@oriola.com
Distribution:
Nasdaq Helsinki Ltd.
Key media
Released by:
Oriola Corporation
Corporate Communications
Orionintie 5
02200 Espoo
www.oriola.com